BioSpace News Archive

c-LEcta has announced that it has reached an agreement with Kerry Group for it to acquire a majority shareholding of the company.

Calliditas Therapeutics AB announced that the first patient has been randomized in the company’s pivotal phase 2b/3 TRANSFORM study in patients with primary biliary cholangitis.

Cerevel Therapeutics today announced positive results from its Phase 1 healthy volunteer clinical trial to evaluate darigabat, a novel alpha-2/3/5 selective GABAA receptor positive allosteric modulator (PAM), in acute anxiety.

Cingulate Inc. today announced that Shane J. Schaffer, Chairman and Chief Executive Officer, will present a company overview at the Aegis Capital Corp. Virtual Conference on February 24, 2022, at 10:30 a.m. ET.

ArriVent Biopharma, Inc., industry leaders dedicated to accelerating the global development of innovative biopharmaceutical products, today announced the appointment of Bahija Jallal, Ph.D. to its Board of Directors.

Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that NASDAQ has halted trading of the Company’s common stock.

Lantern Pharma today announced that it is expanding opportunities for its portfolio of drug candidates and A.I. drug discovery platform into additional rare pediatric cancers through a collaboration with The Greehey Children’s Cancer Research Institute (GCCRI) at the University of Texas Health Science Center at San Antonio (UTHSCSA).

908 Devices Inc. today announced it will report financial results for the fourth quarter and full year 2021 after market close on Monday, March 7, 2022.

BriOri BioTech announces it has received a March 1, 2022, patent issue notification for “Topical Compositions Containing Rofecoxib and Methods of Making and Using the Same.”

Quipt Home Medical Corp. today announced its first quarter fiscal 2022 financial results and operational highlights.